BSP, particularly when evaluated alongside other biomarkers such as hormone receptors or prostate-specific antigen (PSA), holds potential to facilitate early cancer detection, guide treatment strategies and provide valuable insights into treatment response and disease progression. Here, KLK3 is linked to cancer.